The Current Ratio as of September 2024 (TTM) for Merus N.V. (MRUS) is 9.97

According to Merus N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 9.97. This represents a change of 48.68% compared to the average of 6.71 of the last 4 quarters.

Merus N.V. (MRUS) Historical Current Ratio (quarterly & annually)

How has MRUS Current Ratio performed in the past?

The mean historical Current Ratio of Merus N.V. over the last ten years is 5.84. The current 9.97 Current Ratio has changed 16.98% with respect to the historical average. Over the past ten years (40 quarters), MRUS's Current Ratio was at its highest in in the March 2017 quarter at 17.02. The Current Ratio was at its lowest in in the September 2014 quarter at 0.

Merus N.V. (MRUS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Merus N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Merus N.V. (MRUS) Average Current Ratio

How has MRUS Current Ratio performed in the past?

The current Current Ratio of Merus N.V. (MRUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Merus N.V. (MRUS) Current Ratio vs. Peers

How is MRUS’s Current Ratio compared to its peers?

Merus N.V.’s Current Ratio is greater than Anebulo Pharmaceuticals, Inc. (5.32), greater than Adagene Inc. (2.50), less than Acrivon Therapeutics, Inc. Common Stock (16.16), greater than AnaptysBio, Inc. (9.09), less than Mineralys Therapeutics, Inc. (11.20), less than Crinetics Pharmaceuticals, Inc. (16.09), greater than Inhibrx, Inc. (6.20), less than Lyell Immunopharma, Inc. (16.19), greater than Kronos Bio, Inc. (8.49), less than Kura Oncology, Inc. (14.94), less than Protagonist Therapeutics, Inc. (13.73), less than Replimune Group, Inc. (13.46), less than Cerevel Therapeutics Holdings, Inc. (10.22), less than Vaxcyte, Inc. (17.88), less than Larimar Therapeutics, Inc. (10.93), less than Syndax Pharmaceuticals, Inc. (10.50), greater than Sutro Biopharma, Inc. (3.41),

Build a custom stock screener for Merus N.V. (MRUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Merus N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Merus N.V. (MRUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Merus N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.